Our data indicate that BRAF mutation testing of tumor tissue should be carried out in LCH patients refractory to conventional treatment to identify those patients that may benefit from the salvage therapeutic option of BRAF inhibition. The gene discussed is BRAF; the disease is Langerhans cell histiocytosis.